These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 18757997)

  • 1. Drug eluting stents in patients with diabetes.
    Agostoni P; Van den Branden F
    BMJ; 2008 Aug; 337():a1359. PubMed ID: 18757997
    [No Abstract]   [Full Text] [Related]  

  • 2. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients.
    Billinger M; Beutler J; Taghetchian KR; Remondino A; Wenaweser P; Cook S; Togni M; Seiler C; Stettler C; Eberli FR; Lüscher TF; Wandel S; Jüni P; Meier B; Windecker S
    Eur Heart J; 2008 Mar; 29(6):718-25. PubMed ID: 18272504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
    Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
    Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
    Brilakis ES; Banerjee S
    Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842
    [No Abstract]   [Full Text] [Related]  

  • 8. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stent versus bare-metal stent in acute ST-segment elevation myocardial infarction: a word of caution.
    Gupta M; Budoff MJ
    J Invasive Cardiol; 2010 Apr; 22(4):159-60. PubMed ID: 20351385
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.
    Stettler C; Allemann S; Wandel S; Kastrati A; Morice MC; Schömig A; Pfisterer ME; Stone GW; Leon MB; de Lezo JS; Goy JJ; Park SJ; Sabaté M; Suttorp MJ; Kelbaek H; Spaulding C; Menichelli M; Vermeersch P; Dirksen MT; Cervinka P; De Carlo M; Erglis A; Chechi T; Ortolani P; Schalij MJ; Diem P; Meier B; Windecker S; Jüni P
    BMJ; 2008 Aug; 337():a1331. PubMed ID: 18757996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease.
    Kufner S; de Waha A; Tomai F; Park SW; Lee SW; Lim DS; Kim MH; Galloe AM; Maeng M; Briguori C; Dibra A; Schömig A; Kastrati A
    Am Heart J; 2011 Oct; 162(4):740-7. PubMed ID: 21982668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.
    Stettler C; Allemann S; Egger M; Windecker S; Meier B; Diem P
    Heart; 2006 May; 92(5):650-7. PubMed ID: 16251229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
    Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
    N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.
    de Araujo Goncalves P; Seabra-Gomes R; Teles R; Almeida M; Aguiar C; Raposo L; Ferreira J; Pereira Machado F
    Heart; 2006 Aug; 92(8):1155-6. PubMed ID: 16844874
    [No Abstract]   [Full Text] [Related]  

  • 19. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
    Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
    Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.